Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome

Best Practice & Research. Clinical Haematology
H Miles Prince, Christiane Querfeld

Abstract

Novel systemic therapies are generally prescribed to patients with advanced-stage disease or those with early-stage disease refractory to skin-directed therapies. In general, systemic chemotherapy should be reserved for patients who fail to respond to biological agents. Such biological agents include interferon alfa, bexarotene, histone deacetylase inhibitors (vorinostat, romidepsin), brentuximab vedotin and mogamulizumab. Extracorporeal photopheresis is particularly effective for patients with Sézary Syndrome. Allogeneic transplantation is becoming increasing used for younger patients. Novel agents in advanced development include the monoclonal antibody IPH4102,duvelisib,and the new modified formulation of denileukin diftitox. The choice of agents for patients is typically a balance of patient factors (age, co-morbidities, geographic location), relative efficacy and toxicity.

Citations

Apr 21, 2019·Cytopathology : Official Journal of the British Society for Clinical Cytology·Immacolata CozzolinoPio Zeppa
Dec 17, 2019·Therapeutic Advances in Medical Oncology·Catalina Silva-HirschbergAxel H Schönthal
Jan 2, 2021·Journal of Hematology & Oncology·Katarzyna IżykowskaGrzegorz K Przybylski
Jul 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Natasha IrreraAlessandro Allegra

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.